PMID- 22562097
OWN - NLM
STAT- MEDLINE
DCOM- 20121016
LR  - 20211203
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 6
IP  - 2
DP  - 2012 Aug
TI  - Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in 
      combination with cisplatin, on A2780 ovarian cancer cells.
PG  - 316-20
LID - 10.3892/mmr.2012.902 [doi]
AB  - Death receptor 5 (DR5) antibody (D-6) is a monoclonal antibody directed against 
      DR5. The aim of this study was to explore the apoptosis-inducing effects of DR5 
      (D-6), alone or in combination with cisplatin, on A2780 ovarian cancer cells. The 
      cells were treated with various concentrations of cisplatin and/or DR5 (D-6), or 
      a combination of both. For the control group, the cells were treated only with 
      culture medium. Twenty-four hours after the culture, the morphological changes of 
      each group were observed under an inverted microscope. The cell growth inhibition 
      rates were also analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium 
      bromide (MTT) assays, and the apoptosis was analyzed by flow cytometry. Western 
      blotting analysis was used to detect the intracellular reaction. Our results 
      showed that DR5 monoclonal antibody (D-6) was able to induce the apoptosis and 
      increase the cell growth inhibition rates of ovarian cancer cells in a 
      dose-dependent manner, and the effect was enhanced by cisplatin. There were 
      significant morphological changes, a higher cell growth inhibition rate and 
      apoptosis rate and lesser expression of caspase-3, 8, 9 precursors in the cells 
      treated with both cisplatin and DR5 (D-6). The combination treatment of the DR5 
      monoclonal antibody (D-6) with cisplatin may be a promising treatment for ovarian 
      cancer.
FAU - Jiang, Qin
AU  - Jiang Q
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital, 
      Sichuan University, Chengdu, Sichuan 610041, PR China.
FAU - Zhu, Hong
AU  - Zhu H
FAU - Liang, Baoquan
AU  - Liang B
FAU - Huang, Yan
AU  - Huang Y
FAU - Li, Chunmei
AU  - Li C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120503
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Culture Media)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (Tetrazolium Salts)
RN  - 0 (Thiazoles)
RN  - EC 3.4.22.- (Casp8 protein, mouse)
RN  - EC 3.4.22.- (Caspase 8)
RN  - EUY85H477I (thiazolyl blue)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Murine-Derived/*pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - *Apoptosis
MH  - Blotting, Western
MH  - Caspase 8/metabolism
MH  - Cell Line, Tumor
MH  - Cisplatin/*pharmacology
MH  - Culture Media/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - Female
MH  - Flow Cytometry
MH  - Mice
MH  - Ovarian Neoplasms/*metabolism/pathology
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/*immunology
MH  - Signal Transduction
MH  - TNF-Related Apoptosis-Inducing Ligand/metabolism
MH  - Tetrazolium Salts/metabolism
MH  - Thiazoles/metabolism
OTO - NOTNLM
OT  - monoclonal antibody (D-6) against death receptor 5
OT  - cisplatin
OT  - ovarian cancer cell
OT  - apoptosis
OT  - TNF-related apoptosis-inducing ligand
EDAT- 2012/05/09 06:00
MHDA- 2012/10/17 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/02/26 00:00 [received]
PHST- 2012/04/26 00:00 [accepted]
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/10/17 06:00 [medline]
AID - 10.3892/mmr.2012.902 [doi]
PST - ppublish
SO  - Mol Med Rep. 2012 Aug;6(2):316-20. doi: 10.3892/mmr.2012.902. Epub 2012 May 3.